The efficacy of anthracyclines is undermined by potential life-threatening cardiotoxicity. Cardiotoxicity is dependent upon several factors and the timing to its development is variable. Moreover, as adjuvant therapy with trastuzumab often follows, a close monitoring of cardiac function in those treated with anthracyclines is mandatory. Left ventricular ejection fraction (LVEF) by echocardiography is currently used for monitoring cardiotoxicity; however, LVEF has numerous limitations. Two-dimensional strain imaging may provide a more sensitive measure of altered LV systolic function, so the aim of the present study was to compare LVEF and LV systolic strain before and after anthracyclines.
Introduction
Four decades following their discovery, anthracyclines remain among the most widely prescribed anticancer agents; however, their efficacy is undermined by potential life-threatening cardiotoxicity. 1 -3 As cardiotoxicity is dependent upon a number of treatment and patient-related factors and the timing to its development is variable, 4 ,5 a close monitoring of cardiac function before, during, and after anthracycline treatment is mandatory. 5, 6 Currently, resting left ventricular ejection fraction (LVEF) by two-dimensional (2D) echocardiography is the key parameter used to identify and monitor anthracycline-induced cardiotoxicity. LVEF, however, has numerous technical limitations and is a measure of global function, unable to detect subtle regional changes in myocardial mechanics. 7 -10 The recently developed myocardial strain imaging may provide a more sensitive and reproducible measurement of altered LV systolic function.
The aim of the present study was to compare LVEF and LV systolic strain measured with 2D strain imaging before and immediately after anthracycline chemotherapy. We hypothesized that global LV systolic strain measures would prove more sensitive than LVEF in detecting early anthracycline-induced systolic dysfunction and would detect subclinical regional LV systolic dysfunction prior to overt changes in global function.
Methods
Ethics approval for the study was granted by the Sydney West Area Health Service Research Ethics Committee and the University of Sydney, and written informed consent was obtained from all participants. Fifty-two consecutive anthracycline naïve women with histologically confirmed breast cancer were prospectively recruited prior to any thoracic radiotherapy. All participants were recruited at initial review at Westmead Hospital, although subsequent cancer treatment was administered at one of four affiliated sites (depending on proximity to the patient's residence). A detailed record of the administered cumulative anthracycline dose was documented.
The clinical history, physical examination, and echocardiogram were used to establish eligibility. Exclusion criteria included LVEF before chemotherapy of ,50%, rhythms other than sinus, more than mild valvular stenosis or regurgitation, prosthetic valve, or pacemaker. A detailed cardiac history was obtained at recruitment including clinical risk factors for heart disease (hypertension, diabetes, cholesterol, smoking history, and diabetes). Height was measured at baseline, whereas weight and blood pressure were measured at the time of each echocardiogram. Patients were also evaluated for any cardiac symptoms especially those of cardiac failure.
The initial echocardiogram was performed prior to the commencement of chemotherapy (ideally 1 week before). The follow-up echocardiogram was performed 1 week following the completion of chemotherapy (i.e. 12 or 18 weeks after the first study, depending on whether the patient had four or six cycles of chemotherapy, respectively) and always before the commencement of trastuzumab or thoracic radiotherapy. All echocardiograms were performed at a single site by either of two experienced sonographers using a Vivid 7 digital ultrasound system (GE Medical Systems, Norway) with a 2.5 MHz variable frequency transducer.
A comprehensive transthoracic echocardiogram was performed with patients in the left lateral position. Images were obtained from the parasternal, apical, and subcostal views. LVEF was measured by Simpson's method according to the recommendations of the European Association of Echocardiography 11 and measured at the time of acquisition without reference to previous measurements. Clinically significant reductions in LVEF were defined as ≥10% from before chemotherapy or an absolute LVEF ,50% after chemotherapy. Depth-adjusted 2D images of the LV in the parasternal short axis at the level of the papillary muscles and in the apical four-, two-chamber, and long-axis views were acquired and stored for off-line measurement of 2D speckle-tracking myocardial strain (with EchoPac PC versions 6.0, GE Healthcare, UK) ( Figure 1) . Frame rates were optimized at the time of acquisition to between 50 and 70 fps. To ensure reproducibility and accuracy, systole was defined as the interval from aortic valve opening to closure, measured with pulsed-wave Doppler sampling of blood flow in LV outflow tract.
The LV regions of interest for strain analysis were manually selected by marking the endocardial border at end-systole in the appropriate imaging plane. Traces from each segment were inspected to confirm that peak systolic strain was measured prior to aortic valve closure and the tracking quality of all images was identified prior to analysis using the software scoring table on the off-line measuring package. Tracking quality was over-ridden in segments with no more than two rejected regions where the observer deemed tracking quality to be clearly acceptable. Images with persistently unacceptable tracking quality (more than two segments) were excluded from the final analysis.
Strain measurements were made from three consecutive cardiac cycles and then averaged in order to obtain peak systolic regional strain and strain rate in the longitudinal, radial, and circumferential planes ( Figure 1) . Global peak systolic strain and strain rates were calculated by averaging the six regional values in the apical four-chamber and parasternal short-axis views at the mid-papillary level to measure longitudinal, radial, and circumferential strain, respectively. Additionally, in a subgroup of 19 participants with optimal image quality, longitudinal strain was measured from the apical two-chamber and long-axis views and global (apical triplane) longitudinal strain was calculated as an average of 18 segments.
Ten participants in whom longitudinal, radial, and circumferential strain measurements were all possible were randomly selected in order to calculate inter-and intraobserver variability, with differences reported as mean difference + standard deviation (SD). LV systolic strain and LVEF measurements were repeated by a different observer (blinded to previous results) in order to measure interobserver variability. Intraobserver variability for LV systolic strain and LVEF was assessed by the same observer on a different occasion from the same digital data, using an offline system. Differences are reported as mean error + SD of 10 measurements.
All values were expressed as a mean + SD, unless otherwise stated. The effect of anthracycline therapy was examined with a repeatedmeasures analysis of variance (ANOVA). Paired t-tests were used to compare LV segmental strain parameters before and after chemotherapy. Linear regression analysis and Pearson's correlations were performed to examine the relationship of LV systolic strain parameters to cumulative anthracycline dose and age. A x 2 analysis was used to assess the effect of baseline clinical risk factors on altered LV systolic function at follow-up, while univariate analysis was performed to evaluate the effect of alteration in strain to cumulative anthracycline dose, age, and clinical risk factors. Data were analysed using SPSS version 15 (SPSS Inc., Chicago, IL, USA) and considered significant if P , 0.05.
Results
All 52 participants recruited into the study had a baseline echocardiogram before chemotherapy and a follow-up echocardiogram immediately after completing chemotherapy. Four (n ¼ 34) or six cycles (n ¼ 18) of anthracycline chemotherapy (doxorubicin or epirubicin) were administered, as determined by the oncology team. Patient demographics and clinical characteristics are presented in Table 1 . Measurement of biplane LVEF was possible in 50 of the 52 participants (96%). LV myocardial systolic strain measurements were feasible in 47 of the 52 participants (90%), and before chemotherapy, strain measurements were consistent with previously reported normal measurements. 12 Paired measurements of longitudinal, radial, and circumferential strain were possible in 41 of these 47 (87%). Limited image quality before and/or after chemotherapy meant that LVEF and strain measurements were not possible in all participants (image quality was limited most often by left-sided mastectomy and/or breast implant).
No participant reported symptoms of cardiac failure during the time of follow-up. No significant difference in the LV dimensions before and after chemotherapy was observed. A statistically significant reduction in the average LVEF after chemotherapy was observed ( Table 2) ; however, no participant had a reduction in LVEF of ≥10% after treatment. In 14 participants, LVEF fell to Comparison of LVEF and LV systolic strain before and after anthracyclines below 55%. In one participant, LVEF was ,50% after chemotherapy; in this case, LVEF dropped from 56% before to 47% after chemotherapy.
Global longitudinal 2D strain after chemotherapy was significantly reduced; the average global longitudinal strain value dropped from 217.8 to 216.3% (P , 0.01; Table 2 ). In 21 of the 44 participants (48%), global longitudinal strain was reduced by .10% from before chemotherapy and reduced in 7 of the 44 participants (16%) by .20%. Longitudinal strain after chemotherapy was reduced by greater than the mean 2 1 SD of the baseline strain measurement in 12 of the 44 (27%) and by greater than the mean 2 2 SD in 6 of the 44 participants ( Table 2) . In a subgroup, longitudinal strain was measured as a global composite from the apical four-, two-chamber, and long-axis views. A similar reduction of .10% global longitudinal strain was observed in this measurement in 12 of 19 patients ( Table 3) . Participants with an LVEF of ≤55% after anthracycline chemotherapy (but not reduced by .10%) had significantly reduced global longitudinal strain compared with those with LVEF after chemotherapy of .55% (P ≤ 0.01).
Global radial strain after chemotherapy was also significantly reduced; the average global radial strain dropped from 40.5% before to 34.3% (P , 0.01) after treatment ( Table 2 ). In 24 of the 41 participants (59%), global radial strain was reduced by .10% after chemotherapy, with radial strain being reduced in 19 of the 41 participants (46%) by .20% ( Table 2 ). Similar to longitudinal strain, a reduction after chemotherapy of more than the mean 2 1 SD of the before treatment measurement was observed in 16 of the 41 participants (39%). In contrast, global circumferential LV strain after chemotherapy remained largely unchanged from beforehand ( Table 2) ; only three participants' (6%) global circumferential strain was reduced by≥ 20% after chemotherapy.
Regional analysis of longitudinal LV 2D strain revealed significant reductions in all but the apical lateral segment after chemotherapy (Table 4) . Regional analysis of radial strain revealed significantly reduced measurements in three of the six regions (the anteroseptal, septal, and inferior segments) after chemotherapy ( Table 5) . However, regional analysis of circumferential strain showed a significant reduction in the septal segment only ( Table 6) .
Variation in peak LV systolic strain between regions and also within regions was observed. This variation was greatest in the radial plane and least in the circumferential plane, as demonstrated by greater radial strain SDs. In addition to global and regional strain, the peak systolic strain rate was measured, although no significant reduction was observed in systolic strain rate between paired measurements ( Table 7) .
The type of anthracycline and cumulative anthracycline dosage were recorded for all participants. The maximum doxorubicin dose was 318 mg/m 2 and the maximum epirubicin dosage was 581 mg/m 2 . No significant correlation between anthracycline type or dosage and reductions in LVEF or systolic strain was found.
The x 2 analysis was used to assess the impact of baseline clinical risk factors (hypertension, diabetes, cholesterol, smoking history, and history of ischaemic heart disease) and reduced echocardiographic LV systolic strain measurements at follow-up. No significant association between cardiac risk factors and the reduction in strain measurements was observed when tested individually or together; there was no significant difference in blood pressure measurement before and after chemotherapy. Univariate analysis between age, clinical risk, and cumulative anthracycline dose to change in global strain before and after treatment showed no significant correlation between any of the parameters examined. The inter-and intraobserver differences in the measurement of strain were similar (interobserver vs. intraobserver); for global longitudinal strain, the mean interobserver difference was 21.73 + 1.0 and the mean intraobserver difference was 20.86 + 0.59. For global radial strain, the mean interobserver difference was 5.0 + 7.80 and the mean intraobserver difference was 3.40 + 12.40. For global circumferential strain, the mean interobserver difference was 1.48 + 1.24 and the mean intraobserver difference was 1.62 + 1.10.
Discussion
The principal findings of this study suggest that myocardial strain imaging may be more sensitive than LVEF in detecting changes in LV systolic function early after therapeutic doses of anthracycline chemotherapy. While .10% reductions in longitudinal and radial peak LV systolic strain measurements were observed after chemotherapy in 50% of the participants and 27% of participants had a reduction in longitudinal strain and 39% had a reduction in radial strain greater than mean 2 1 SD of baseline strain measurements, a corresponding reduction in LVEF ≥10% was not observed in any participant after chemotherapy. Furthermore, Comparison of LVEF and LV systolic strain before and after anthracyclines participants with an LVEF of ≤55% after anthracycline chemotherapy had significantly reduced global longitudinal strain compared with those with an LVEF of .55%. While these observations suggest that longitudinal and radial strain identify early impairment of myocardial systolic function, radial strain measurements had high variability. Determining the significance of the observed reductions will require long-term follow-up before strain is used with established markers of cardiotoxicity in decisions related to changes in therapy. LV muscular anatomy is complex; overall, it has a helical configuration, with three 'layers' within the ventricular wall. The muscle 'layers' do not comprise discrete muscle groups, but are classified according to the predominant orientation of myocytes. 13 LVEF is the current standard method for monitoring systolic function in chemotherapy patients; however, LVEF relies upon geometric assumptions for its calculation. 8 Moreover, LVEF is a measure of global function that is unable to determine which muscle layer is affected. In contrast, strain imaging can measure both regional and global function and does not rely on assumptions about cardiac geometry. The contemporary 2D speckle-tracking strain imaging technique is distinct from the older 'tissue' Dopplerbased technique, as it is semi-automated, utilizes low frame rates, and importantly is relatively angle-independent. 14 We observed significant reductions in global longitudinal and radial systolic strain measurements after chemotherapy in the absence of any reported symptoms ( Table 2) . Reduced global longitudinal strain with preserved LVEF has been previously reported in other disease settings. 15 -17 Reduced longitudinal and radial strain using the older tissue Doppler-based strain technique has been previously reported in a small study of 16 patients over the age of 65 after pegylated anthracyclines. 7 A reduction in radial 2D strain has been reported in an animal model early after anthracycline therapy. 18 Our observation of reduced global longitudinal and radial strain early after anthracycline chemotherapy was made in a larger group of 52 patients and with the semiautomated 2D strain imaging technique. Sawaya et al. 19 recently reported that reduced longitudinal and radial strain after 3 months of cancer treatment could predict the later development of cardiotoxicity while reduced LVEF after 3 months could not. However, their study participants were a heterogeneous group that included participants who had received anthracyclines, adjuvant therapy with trastuzumab, and thoracic radiotherapy. Therefore, our observations differ significantly for two important reasons; we studied patients after anthracycline treatment only (with no radiotherapy or adjuvant trastuzumab) and observed reduced longitudinal and radial strain 1 week following anthracycline therapy. It must be noted, however, that the variability of radial strain measurements using the currently available techniques makes it difficult to determine whether the reductions observed in radial strain after chemotherapy represent a true reduction or can be accounted for by the variability of the measurement. In contrast to longitudinal and radial strain, global circumferential systolic strain remained largely unchanged after chemotherapy ( Table 2) . Reduced longitudinal strain, with preserved circumferential strain and preserved LVEF in long-term cancer survivors treated with anthracyclines and/or radiotherapy, was reported recently by Tsai et al. 20 Reduced longitudinal strain in long-term survivors treated with anthracyclines and in a subgroup treated with adjuvant trastuzumab was also reported recently by Ho et al. 21 We additionally observed a reduction in radial strain parameters, suggesting a more generalized myocardial involvement consequent to oxidative stress-mediated anthracycline chemotherapy. Fallah-Rad et al. 22 recently reported significantly reduced longitudinal and radial strain after anthracyclines in participants who later developed trastuzumab-induced cardiomyopathy, but did not report any circumferential measurements. In our study, global circumferential LV strain remained largely unchanged after chemotherapy. Paired analysis for within patient differences revealed that global circumferential strain was reduced ≥20% in only three participants. Interestingly, the one participant with an important drop in LVEF to 47% after chemotherapy was one of these three. Although it is inappropriate to extrapolate an observation in a single patient, it suggests that changes in circumferential strain occur later than changes in the other two axes and that larger reductions in LVEF may occur in association with significantly reduced circumferential strain. Significant reductions in regional longitudinal and radial systolic strain after chemotherapy were observed (Tables 4 and 5) in the LV lateral wall and most often in the septal regions, possibly indicating a regional heterogeneity in the development of systolic dysfunction. These novel findings suggest that identifying reduced strain in the LV lateral wall may be a way of monitoring myocardial function in this setting. Regional variation in peak LV systolic strain was observed, in keeping with observations from the previous reports, 12, 17 and is likely due to the variable LV fibre orientation shown to exist within and between subjects . 13 However, as 2D strain is dependent on image quality, some regional variation may be attributable to this as well. Contrary to our observations related to strain, no significant reduction in global or regional systolic strain rate was observed after chemotherapy. This finding may indicate that the degree of systolic myocardial deformation is impaired prior to reduction in the rate at which deformation occurs. Alternatively, it may be that frame rates between 50 and 70 fps are not high enough to detect changes in strain rate.
In adults, heart failure induced by the anthracycline doxorubicin has been reported to occur in 4-5% at a cumulative dose of 500-550 mg/m 2 and up to 36% at a cumulative dose of 600 mg/m 2 or more. ) and supports our observation of reduced LV systolic strain early after therapeutic doses of anthracycline chemotherapy.
In keeping with previous reports, our results indicate that clinically significant reductions in LVEF (LVEF reductions .10% or absolute reductions in LVEF to ,50%) following low-dose anthracyclines are rare. Our results also indicate that strain may detect early impairment of myocardial systolic function. The clinical relevance of these findings will require longer-term follow up for future cardiovascular events in this patient group.
Early initiation of heart failure treatment appears important for the recovery of LV function in patients who experience a significant reduction in LVEF due to anthracyclines. 26 Therefore, early identification of impaired systolic function is vital. Furthermore, given that many breast cancer patients first treated with anthracyclines will then receive trastuzumab, identifying patients at greater risk of developing cardiotoxicity is of considerable advantage. Early identification of those with significant reductions in strain (even in the absence of reduced LVEF) would enable targeted monitoring, together with the institution of supportive therapy with angiotensin-converting enzymeinhibitors or b-blockers, should further treatment with trastuzumab be required. No significant association between cardiac risk factors (see the Methods section) when tested individually or together and reduced global strain was found; no difference in blood pressure measurements before and after treatment was observed; however, in order to confirm a lack of association between these cardiovascular risk factors and reduced strain measurements, larger studies of more participants with coexistent morbidities would be required. Only one participant in this study had a postchemotherapy LVEF of ,50%. Larger-scale studies over an extended period are required in order to determine the clinical relevance of the observed early reduction in strain measurements.
Our present study has some limitations. It was performed in a relatively small group of patients and does not provide longer-term follow-up on the clinical implications of early anthracycline-induced changes in myocardial strain. Our study does not include another imaging modality, such as magnetic resonance imaging, or the serial evaluation of cardiac biomarkers or ECG, which may provide additional information. Performance of biomarker testing was beyond the scope of the present study. Variability of strain measurements is an inherent limitation of the technique; however, our measurements are similar to other published data. 12, 21, 22 As the variability with radial strain is highest, despite the reduction in the mean value, it remains difficult to determine its real clinical value.
Our results indicate that 2D strain detects early reductions in global and regional systolic strain that may signify early impairment of myocardial systolic function immediately after anthracycline chemotherapy. Longer-term follow-up is needed to determine the clinical significance of the results of this study and whether early reduction in strain parameters results in the identification of future LV dysfunction in this clinical setting. Early identification of impaired systolic function will enable monitoring as well as targeted cardioprotective therapy in patients who require further (potentially life-saving) treatment with trastuzumab.
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